4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0000950170-25-109838
Chief Scientific Officer sold 8,500 shares at an average $15.00 ($127,466)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2025-08-15 | Sale 10b5-1 | −8,300 | $14.98 | $124,308 | 426,842 | D |
| Bredt David Chief Scientific Officer | 2025-08-15 | Sale 10b5-1 | −200 | $15.79 | $3,158 | 426,642 | D |
| Open-market sales · 8,500 sh · avg $15.00 · $127,466 | |||||||
Loading xslF345X05/ownership.xml…